MRUS Live signals | Maximize Profits with Getagraph.com

BUY 157669 min ago

@ $42.61

Issued: 14 Feb 2024 @ 14:47

Return: 24.95%

Previous signal: Feb 13 - 15:34

Previous signal: Sell

Return: 1.44 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Stats
Today's Volume	1.72M
Average Volume	874 206
Market Cap	3.12B
EPS	$0 ( 2024-05-09 )
Next earnings date	( $-0.780 ) 2024-08-05
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-19.50
ATR14	$0.207 (0.39%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-07	Haddock Jason	Buy	17 688	Share Option (right to buy)
2024-05-07	Pucci Paolo	Buy	8 844	Share Option (right to buy)
2024-05-07	Shuman Harry	Buy	27 550	Share Option (right to buy)
2024-05-07	Lundberg Sven Ante	Buy	360 000	Share Option (right to buy)
2024-05-07	Haddock Jason	Buy	0

INSIDER POWER
85.50
Last 98 transactions
Buy: 3 333 163 \| Sell: 3 625 693

Volume Correlation

Long: -0.53 (weak negative)

Short: 0.04 (neutral)

Signal:(39.064) Neutral

Merus NV Correlation

10 Most Positive Correlations
YMAB	0.925
VERA	0.913
REYN	0.913
HQY	0.912
POWL	0.904
HOWL	0.903
LPLA	0.901
MOR	0.893
PEPG	0.888
SLN	0.883

10 Most Negative Correlations
SGML	-0.931
BIOL	-0.922
CNTY	-0.922
PRSO	-0.918
REVB	-0.915
MKTX	-0.911
OMCL	-0.911
DCOM	-0.91
RSLS	-0.909
WINT	-0.909

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Merus NV Correlation - Currency/Commodity

-0.47
( neutral )

0.19
( neutral )

-0.60
( weak negative )

0.51
( weak )

0.81
( strong )

Merus NV Financials

Annual	2023
Revenue:	$43.95M
Gross Profit:	$-83.46M (-189.91 %)
EPS:	$-3.00

FY	2023
Revenue:	$43.95M
Gross Profit:	$-83.46M (-189.91 %)
EPS:	$-3.00

FY	2022
Revenue:	$41.59M
Gross Profit:	$29.60M (71.19 %)
EPS:	$-2.92

FY	2021
Revenue:	$49.11M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.730

Financial Reports:

No articles found.

Merus NV Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Merus NV

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.